Halozyme Therapeutics Stock News

Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.

Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.

Halozyme Therapeutics Inc (NASDAQ: HALO ) reported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million. The decrease was primarily driven by a decline in revenue under collaboration agreement and product sales, partially offset by an increase in royalty revenue attributable to subcutaneous Darzalex (daratumumab). Revenue for Q4 included $62.6 million in royalties. Adjusted EPS of $0.42 beat Full story available on Benzinga.com

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics press release (HALO): Q4 Non-GAAP EPS of $0.42 beats by $0.01.Revenue of $102M (-16.2% Y/Y) beats by $2.31M.2022 Revenue Guidance of $530 to $560

Halozyme Therapeutics, Inc.'s (HALO) CEO Helen Torley on Q4 2021 Results - Earnings Call Transcript

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics Inc (NASDAQ:HALO) is gearing up for its fourth-quarter earnings report, due out after the close today, in which the company is expected to post profits of 41 cents per share.

Halozyme Therapeutics (NASDAQ:HALO) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is $0.41 and the consensus

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics (HALO) promoted Nicole LaBrosse to the position of senior vice president and CFO, effective immediately.LaBrosse will succeed Elaine Sun, who is stepping

CP, HALO, AMX, ESTA, and GEO have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2021.